MY143793A - Non-tabletted, chewable, individually dosed administration forms - Google Patents

Non-tabletted, chewable, individually dosed administration forms

Info

Publication number
MY143793A
MY143793A MYPI20044643A MYPI20044643A MY143793A MY 143793 A MY143793 A MY 143793A MY PI20044643 A MYPI20044643 A MY PI20044643A MY PI20044643 A MYPI20044643 A MY PI20044643A MY 143793 A MY143793 A MY 143793A
Authority
MY
Malaysia
Prior art keywords
administration forms
dosed administration
individually dosed
tabletted
chewable
Prior art date
Application number
MYPI20044643A
Other languages
English (en)
Inventor
Jose Luis Fabregas Vidal
Antoni Masso Carbonell
Nuria Garcia Gonzalez
Pere Guiro Coll
Original Assignee
Almirall Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34610359&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY143793(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Lab filed Critical Almirall Lab
Publication of MY143793A publication Critical patent/MY143793A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI20044643A 2003-11-10 2004-11-08 Non-tabletted, chewable, individually dosed administration forms MY143793A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200302612A ES2235626B1 (es) 2003-11-10 2003-11-10 Formas de administracion masticables, no comprimidas dosificadas individualmente.

Publications (1)

Publication Number Publication Date
MY143793A true MY143793A (en) 2011-07-15

Family

ID=34610359

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20044643A MY143793A (en) 2003-11-10 2004-11-08 Non-tabletted, chewable, individually dosed administration forms

Country Status (25)

Country Link
US (1) US20070134318A1 (enExample)
EP (1) EP1682097B1 (enExample)
JP (1) JP4879021B2 (enExample)
KR (1) KR20060116821A (enExample)
CN (1) CN1878542A (enExample)
AR (1) AR048050A1 (enExample)
AT (1) ATE492270T1 (enExample)
AU (1) AU2004290517B2 (enExample)
BR (1) BRPI0416215A (enExample)
CA (1) CA2548615A1 (enExample)
CO (1) CO5690531A2 (enExample)
DE (1) DE602004030706D1 (enExample)
EC (1) ECSP066553A (enExample)
ES (2) ES2235626B1 (enExample)
IL (1) IL175285A (enExample)
MY (1) MY143793A (enExample)
NO (1) NO20062723L (enExample)
NZ (1) NZ546375A (enExample)
PE (1) PE20050488A1 (enExample)
RU (1) RU2369379C2 (enExample)
TW (1) TW200526266A (enExample)
UA (1) UA90253C2 (enExample)
UY (1) UY28586A1 (enExample)
WO (2) WO2005048975A1 (enExample)
ZA (1) ZA200602416B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050089559A1 (en) 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
ES2420960T3 (es) 2006-08-23 2013-08-28 Valeant Pharmaceuticals International Derivados de 4-(N-azacicloalquil)anilidas como moduladores de los canales de potasio
AU2007325629A1 (en) 2006-11-28 2008-06-05 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
US8367684B2 (en) 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
WO2009002084A2 (en) * 2007-06-27 2008-12-31 Hanmi Pharm. Co., Ltd. Method for preparing rapidly disintegrating formulation for oral administration and apparatus for preparing and packing the same
IL187159A0 (en) 2007-07-03 2009-02-11 Gur Megiddo Use of metadoxine in relief of alcohol intoxication
US7786146B2 (en) 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
EP2323735A1 (en) 2008-07-29 2011-05-25 Alcobra Ltd. Substituted pyridoxine-lactam carboxylate salts
EP2238976B1 (en) * 2009-04-03 2012-06-27 Hexal AG Oral films comprising 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro- 1H-quinolin-2-one base or salts or hydrates thereof
CA2766107A1 (en) 2009-06-25 2010-12-29 Alcobra Ltd. A method for the treatment, alleviation of symptoms of, relieving, improving and preventing a cognitive disease, disorder or condition
EA021368B1 (ru) * 2011-06-21 2015-06-30 Общество С Ограниченной Ответственностью "Консорциум-Пик" Препарат кардиопротекторного действия
CN105911057B (zh) * 2016-06-22 2018-10-19 扬州一洋制药有限公司 一种铝镁加混悬液的质量控制方法
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
PH12022551110A1 (en) 2019-11-08 2024-02-26 Xenon Pharmaceuticals Inc Methods of treating depressive disorders
JP2024508660A (ja) 2021-02-09 2024-02-28 ゼノン・ファーマシューティカルズ・インコーポレイテッド 快感消失の治療に使用するための電位依存性カリウムチャネル開口薬
CN113425694A (zh) * 2021-07-02 2021-09-24 杭州蚕宝生物技术有限公司 一种石斛生物碱口腔崩解片剂及其制备方法
US12053484B2 (en) 2021-10-29 2024-08-06 Medicated Chews, Llc Simethicone chewable composition

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5645411A (en) * 1979-09-20 1981-04-25 Taiho Yakuhin Kogyo Kk Poultice
FR2515035A1 (fr) * 1981-10-26 1983-04-29 Rhone Poulenc Sante Nouvelle forme galenique solide pour administration par voie orale et son procede de fabrication
EP0409432A3 (en) * 1989-07-20 1991-12-11 Warner-Lambert Company Confectionery delivery system
US5433951A (en) * 1993-10-13 1995-07-18 Bristol-Myers Squibb Company Sustained release formulation containing captopril and method
JPH08319232A (ja) * 1995-03-22 1996-12-03 Takeda Chem Ind Ltd 粉粒状組成物
JPH0912463A (ja) * 1995-06-23 1997-01-14 Fujisawa Pharmaceut Co Ltd 口中咀嚼用製剤
US20030216303A1 (en) * 1998-03-06 2003-11-20 Michael Ambuhl Emulsion preconcentrates containing cyclosporin or a macrolide
US6171615B1 (en) * 1998-07-06 2001-01-09 Gattefoss{acute over (e)} Sustained release theophylline formulations, excipient systems and methods of production
US6060078A (en) * 1998-09-28 2000-05-09 Sae Han Pharm Co., Ltd. Chewable tablet and process for preparation thereof
US6652880B1 (en) * 1999-04-01 2003-11-25 R.P. Scherer Technologies, Inc. Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants
EP2298284A3 (en) * 2001-02-14 2013-12-18 GW Pharma Limited Mucoadhesive pharmaceutical formulations
US6692771B2 (en) * 2001-02-23 2004-02-17 Cima Labs Inc. Emulsions as solid dosage forms for oral administration
RU2197094C1 (ru) * 2001-12-26 2003-01-27 Ставрулов Игорь Анатольевич Жевательная резинка

Also Published As

Publication number Publication date
CO5690531A2 (es) 2006-10-31
ATE492270T1 (de) 2011-01-15
AU2004290517A1 (en) 2005-06-02
ECSP066553A (es) 2006-12-20
WO2005048974A2 (en) 2005-06-02
AU2004290517B2 (en) 2010-05-27
EP1682097A2 (en) 2006-07-26
WO2005048974A3 (en) 2006-02-23
ZA200602416B (en) 2009-06-24
AR048050A1 (es) 2006-03-29
IL175285A (en) 2011-04-28
NZ546375A (en) 2009-11-27
EP1682097B1 (en) 2010-12-22
ES2235626A1 (es) 2005-07-01
CN1878542A (zh) 2006-12-13
PE20050488A1 (es) 2005-08-24
ES2358332T3 (es) 2011-05-09
JP4879021B2 (ja) 2012-02-15
TW200526266A (en) 2005-08-16
BRPI0416215A (pt) 2006-12-26
US20070134318A1 (en) 2007-06-14
UY28586A1 (es) 2005-05-31
NO20062723L (no) 2006-06-12
IL175285A0 (en) 2006-09-05
UA90253C2 (ru) 2010-04-26
RU2006120087A (ru) 2007-12-27
RU2369379C2 (ru) 2009-10-10
KR20060116821A (ko) 2006-11-15
DE602004030706D1 (de) 2011-02-03
WO2005048975A1 (en) 2005-06-02
CA2548615A1 (en) 2005-06-02
ES2235626B1 (es) 2006-11-01
JP2007510690A (ja) 2007-04-26

Similar Documents

Publication Publication Date Title
MY143793A (en) Non-tabletted, chewable, individually dosed administration forms
UA74339C2 (uk) Форма для введення, що включає інгібітор протонної помпи у вигляді окремих одиниць, та спосіб їх одержання
AP2397A (en) Matrix for sustained, invariant and independent release of active compounds.
ATE279209T1 (de) Injizierbare pharmazeutische zusammensetzung zur systemischen verabreichung pharmakologisch aktiver wirkstoffe enthaltend mittelkettige triglyceride
AU3708599A (en) Use of pharmaceutical compositions capable of being gelled in periodontology
WO2001019378A3 (en) Solid lipid formulations comprising an inhibitor of lipases and a fatty acid ester of polyols
CA2518918A1 (en) Alpha-hydroxy acid ester drug delivery compositions and methods of use
TWI255720B (en) Novel preparation and administration form comprising an acid-labile active compound and process for production thereof
JP2007510690A5 (enExample)
CA2273960A1 (en) Viral inhibition by long-chain alcohols, alkanes, fatty acids and amides
BR0215303A (pt) Formulações farmacêuticas de base aquosa de pró-drogas solúveis em água de propofol
FI935051A0 (fi) Lanolinderivat som penetrationfraemjande aemnen och anvaendning av dessa i preparat innehaollande laekemedel eller andra biologiskt aktiva substanser
FR2845289B1 (fr) Spheroides, procede de preparation et compositions pharmaceutiques.
PE97199A1 (es) Composiciones solubilizadas de sertralina
CA2251702A1 (en) Biologically active composition
CO4940482A1 (es) Composiciones farmaceuticas conteniendo 3-de-o-acylo lipido monofosforilo a y procedimiento de preparacion
TH73462A (th) รูปยาสำหรับการให้ยาที่กำหนดขนาดยาไว้ในแต่ละหน่วยที่เคี้ยวได้และไม่ได้ทำให้เป็นยาเม็ด
CA2445677A1 (en) Viral inhibition by long-chain alcohols, alkanes, fatty acids and amides
MY142110A (en) Matrix for sustained, invariant and independent release of active compounds